Last reviewed: June 1, 2026
2014Science Translational Medicine
Soluble TREM2 inhibits Tau seeding and progression of Alzheimer's disease
Kleinberger G, Yamanishi Y, Suárez-Calvet M, Czirr E, Lohmann E, Cuyvers E, et al.
Abstract summary
Identified TREM2 proteolytic shedding producing soluble TREM2 (sTREM2) in cerebrospinal fluid. Disease-causing mutations impair TREM2 shedding. Elevated sTREM2 in CSF is associated with Alzheimer's disease and FTD. This work established sTREM2 as a potential biomarker of microglial activity.
Evidence labels
human tissueproteomicsin vitro assay
Targets
Diseases
- Alzheimer's disease
- Frontotemporal dementia
Species
human, mouse
Methods
CSF proteomics, cell biology, flow cytometry
Therapeutic relevance
sTREM2 established as a microglial biomarker. TREM2 shedding modulation is a potential therapeutic avenue.
Last reviewed: June 1, 2026